 Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc. MEI or the Company NASDAQ: MEIP and certain of its officers. The class action, filed in United States District Court for the Southern District of California, and docketed under 20-cv-01543, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired MEI Pharma securities between August 2, 2017, and July 1, 2020, both dates inclusive the Class Period, seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10b and 20a of the Securities Exchange Act of 1934 the Exchange Act and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. 